Boosting Immunity

SurvivX is an early-stage biotech company developing a technology platform of potent innate immunity boosters to revive dysfunctional innate immune cells, which has therapeutic potential in multiple indications such as o.a. sepsis, trauma, major surgery, and as an innovative neoadjuvant (‘primer’ or ‘booster’) in cancer immuno-therapy.

We have a revolutionary new approach towards improving the outcome of diseases. We are developing a unique innate immune enhancer, which we call SUR-101, and is intended as a novel immune stimulating therapeutic and adjuvant.

Read our whole story

How to become part of our journey

We are a young company, and we are full of ambitions. Here is how you can contribute:

Join us as a partner for development

We are looking for partnerships with researchers in the field of immunology and pharmaceutical development, not-for-profits and commercial parties to further develop our business.

Invest in our next stages of development

To fund the development of SUR-101, SurvivX plans to apply for non-dilutive grants and is actively looking for equity investments by smaller and larger private, corporate, and venture capital investors.

Start working for our company

SurvivX is seeking talented people to strengthen our team for the next stages of development from 2024 onwards. If we have current vacancies, they are listed below. But you can always submit an open request, so contact us!